ECOR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ECOR is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has short-term bullish technicals and sits near resistance, but there is no strong proprietary buy signal, no recent news catalyst, and sentiment from hedge funds and insiders is clearly negative. Analyst coverage is still positive, but the lowered target reduces conviction. Given the mixed setup, the better call is to wait rather than buy aggressively now.
ECOR is in a short-term uptrend. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports positive momentum. MACD is above zero, but the histogram is positively contracting, suggesting momentum may be losing strength. RSI_6 at 66.317 is near overbought territory but still within a neutral-to-bullish range. Price at 10.18 is just under R1 at 10.268 and above the pivot at 9.562, so the stock is trading near resistance rather than a clean breakout. Overall, the chart is constructive but not ideal for an immediate long-term entry.
The stock also showed a positive regular market move of 2.52%.
No news in the recent week, so there is no fresh event-driven catalyst. Hedge funds are selling, with selling activity up 171.65% over the last quarter. Insiders are also selling, up 666.36% over the last month. The swing and AI proprietary signals show no buy signal today, and the similar candlestick pattern model points to weakness over the next month.
No latest quarter financial snapshot was available because the provided data returned an error. As a result, there is no reliable quarterly revenue or earnings growth assessment available from the dataset.
Analyst sentiment is still positive but slightly less aggressive than before. On 2026-05-07, Ladenburg lowered the price target to 19.85 from 22 while keeping a Buy rating. That suggests Wall Street still sees upside, but expectations have been trimmed. The pros view is that analysts remain constructive overall; the cons view is that the reduced target and lack of recent catalysts weaken conviction.
